ALTASCIENCES
14.12.2021 18:00:10 CET | Business Wire | Press release
Altasciences ’ pharmaceutical contract manufacturing site in Philadelphia, PA, has been chosen by Respira Technologies, Inc. to manufacture proprietary drug products for the world’s first inhaled smoking cessation therapy. This treatment uses RespiRx™, a vibrating mesh nebulizer (VMN) with a maintenance-free disposable cartridge that reduces and potentially eliminates the risk of patient misuse and non-compliance.
Following a successful Pre-Investigational New Drug (IND) meeting with the Food and Drug Administration (FDA) on November 18, Respira is intending to submit their IND application in 2022 under the 505(b)(2) regulatory pathway.
Respira also plans to create a larger platform approach for active pharmaceutical ingredient (API) delivery, taking advantage of the multi-drug capabilities of their proprietary platform drug delivery system. To date, 91 potential APIs have been identified.
“Our team chooses best-in-class partners, and working with Altasciences has been a great experience overall. Altasciences is playing a big role in advancing Respira’s ambition to secure the FDA’s authorization on a potential breakthrough drug product, and through this collaborative environment, we can change the world of drug development. Altasciences is agile, flexible, and quick, while providing the proven expertise and capability required for cGMP pharma drug product manufacturing. We are thankful for their fast response rate, creativity, and ability to take on the needs of nimble start-ups like Respira ,” said Mario Danek, Founder and CEO at Respira Technologies, Inc.
Altasciences leverages deep expertise in formulation, development, and manufacturing, as well as flexible processes and significant investments in state-of-the-art technologies, to support clients in their research and commercial manufacturing requirements.
“We are delighted to be partnering with Respira Technologies, Inc. on this new and exciting technology. Our team has truly enjoyed having the opportunity to work with a world-class organization that quickly makes key decisions to ensure we meet accelerated timelines,” stated Ben Reed, Executive Vice President of Operations at Altasciences.
More information on Respira Technologies, Inc.’s program can be found here .
About Altasciences
Altasciences is a forward-thinking, mid-size contract research organization offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services . For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing , clinical pharmacology and proof of concept , bioanalysis , program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211214006040/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Advanced Sterilization Products (ASP) Acquires a Majority Stake in UV Smart24.6.2026 12:00:00 CEST | Press release
Advanced Sterilization Products (ASP), part of the Infection Prevention group of companies within Fortive (NYSE: FTV), announced today it has acquired a majority share of UV Smart, a leader in High Level Disinfection technology in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260624367451/en/ UV Smart is renowned for its UV-C High Level Disinfection (HLD) technology that enables faster, safer and lower-cost HLD for specialty scopes. “UV Smart’s dedicated customer relationships and highly skilled team are key strengths that align perfectly with ASP’s long-term growth strategy of infection prevention,” shared Daan Hoek, co-founder of UV Smart. He continued, “Where current cleaning & disinfection processes of TEE probes can often take hours, UV Smart’s premier product, the D60, achieves high-level disinfection using UV-C light in just minutes. For healthcare providers, the D60 represents a significant improvement in ef
Quectel Introduces NXP-based FCM365X Wi-Fi 6, Bluetooth LE 5.4, Zigbee and Thread Module for Smart Home and Industrial IoT Solutions24.6.2026 10:00:00 CEST | Press release
Quectel Wireless Solutions, a global end-to-end IoT solutions provider, today announces the launch of the FCM365X, a dual band Wi-Fi 6 and Bluetooth Low Energy (BLE) 5.4 module that is based on the NXP® Semiconductors RW612 wireless MCU and supports multiple protocols, including Zigbee and Thread. The module is powered by a high-performance Arm® Cortex®-M33 processor with TrustZone® technology, operating at up to 260MHz. It integrates 1.2MB of SRAM and 8MB of Flash memory, with optional PSRAM expansion available, delivering the performance and memory capacity required for demanding IoT applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260624781458/en/ Quectel introduces NXP-based FCM365X Wi-Fi 6, Bluetooth LE 5.4, Zigbee and Thread module for smart home and industrial IoT solutions As smart home and industrial IoT ecosystems continue to evolve, support for interoperable standards such as Thread and Zigbee is becom
Boomi Announces Its FY26 EMEA Customer Innovation Award Winners24.6.2026 10:00:00 CEST | Press release
Award winners recognised at Boomi World Tour London for driving data activation, simplifying complexity, and delivering measurable business impact across the region Boomi, the data activation company for AI, today announced the EMEA winners of its FY26 Boomi Customer Innovation Awards, at Boomi World Tour London, taking place 23–24 June 2026 at the Park Plaza Westminster Bridge, London. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260624407145/en/ Boomi Announces Its FY26 EMEA Customer Innovation Award Winners Across Europe, the Middle East and Africa, a new generation of organisations is redefining what it means to be a data-driven business. This year's EMEA Customer Innovation Award winners have done more than implement technology, they have fundamentally changed how their organisations operate, compete, and grow. Working with the Boomi Enterprise Platform, they have turned fragmented data into strategic advantage, repla
Takeda Announces New Assignments of Directors and Appointment of Julie Kim as Representative Director, President and CEO24.6.2026 09:05:00 CEST | Press release
Board of Directors appoints Julie Kim as Representative Director, President & CEO following shareholder vote Announces new appointments and assignments of directors In the final step of its 18-month CEO transition, Takeda (TOKYO:4502/NYSE:TAK) today announced that Julie Kim was officially appointed Takeda’s Representative Director, President and Chief Executive Officer. During the 150th Annual General Meeting of Shareholders, which took place in Osaka, Japan, shareholders elected Julie as a new internal director to the Board of Directors. Following the vote and conclusion of the meeting, the Board of Directors appointed her as Representative Director, President & CEO. Upon conclusion of the meeting, former president & CEO Christophe Weber retired from the Company and the Board. Chair of the Board of Directors Meeting, Masami Iijima, commented: “On behalf of Takeda’s Board of Directors, I would like to congratulate Julie Kim on becoming Takeda’s President and CEO. The Board of Directors
LTM Joins Athena, a Chainguard-led Industry Coalition to Help Secure Open Source Software in the AI Era24.6.2026 08:30:00 CEST | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, has joined Athena, a new industry coalition led by Chainguard, focused on protecting open source software from the rising threat of AI-driven vulnerabilities. Athena brings together leading organizations across the global software ecosystem to address an urgent challenge. As frontier AI models advance, they are increasingly capable of identifying novel vulnerabilities in open source software at machine speed, often faster than traditional disclosure and patching processes can respond. As AI accelerates both software development and the discovery of vulnerabilities, the window between a flaw being identified and being exploited has narrowed sharply. Athena is designed to close this gap through shared intelligence, coordinated action, and pre-disclosure remediation across the ecosystem. The coalition supports vulnerability management end to end, from discovery and analysis to patching, layered mitigations, and upstr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom